The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study
Open accessAbstract
BACKGROUND: Activated phosphoinositide 3-kinase δ syndrome (APDS) 2 (p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI]-R1), a recently described primary immunodeficiency, results from autosomal dominant mutations in PIK3R1, the gene encoding the regulatory subunit (p85α, p55α, and p50α) of class IA phosphoinositide 3-kinases. OBJECTIVES: We sought to review the clinical, immunologic, and histopathologic phenotypes of APDS2 in a genetically defined international patient cohort. METHODS: The medical and biological records of 36 patients with genetically diagnosed APDS2 were collected and reviewed. RESULTS: Mutations within splice acceptor and donor sites of exon 11 of the PIK3R1 gene lead to APDS2. Recurrent upper respiratory tract infections (100%), pneumonitis (71%), and chronic lymphoproliferation (89%, including adenopathy [75%], splenomegaly [43%], and upper respiratory tract lymphoid hyperplasia [48%]) were the most common features. Growth retardation was frequently noticed (45%). Other complications were mild neurodevelopmental delay (31%); malignant diseases (28%), most of them being B-cell lymphomas; autoimmunity (17%); bronchiectasis (18%); and chronic diarrhea (24%). Decreased serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell lymphopenia (88%) associated with an increased frequency of transitional B cells (93%), and decreased numbers of naive CD4 and naive CD8 cells but increased numbers of CD8 effector/memory T cells were predominant immunologic features. The majority of patients (89%) received immunoglobulin replacement; 3 patients were treated with rituximab, and 6 were treated with rapamycin initiated after diagnosis of APDS2. Five patients died from APDS2-related complications. CONCLUSION: APDS2 is a combined immunodeficiency with a variable clinical phenotype. Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation, and lymphoma similar to APDS1/PASLI-CD. Immunoglobulin replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase δ inhibitors are possible treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lucas, C. L., Kuehn, H. S., Zhao, F., Niemela, J. E., Deenick, E. K., Palendira, U., Avery, D. T., Moens, L., Cannons, J. L., Biancalana, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2771 · Cited by 673
Self-citationPhosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage
Angulo, I., Vadas, O., Garçon, F., Banham-Hall, E., Plagnol, V., Leahy, T. R., Baxendale, H., Coulter, T., Curtis, J., Wu, C., et al. (2013) · Science · doi:10.1126/science.1243292 · Cited by 636
Self-citationThe genetic landscape of mutations in Burkitt lymphoma
Love, C., Sun, Z., Jima, D., Li, G., Zhang, J., Miles, R., Richards, K. L., Dunphy, C. H., Choi, W. W. L., Srivastava, G., et al. (2012) · Nature Genetics · doi:10.1038/ng.2468 · Cited by 597
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Okkenhaug, K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095946 · Cited by 446
Lucas, C. L., Zhang, Y., Venida, A., Wang, Y., Hughes, J., McElwee, J., Butrick, M., Matthews, H., Price, S., Biancalana, M., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20141759 · Cited by 291
Self-citationA human immunodeficiency caused by mutations in the PIK3R1 gene
Deau, M.-C., Heurtier, L., Frange, P., Suarez, F., Bole-Feysot, C., Nitschke, P., Cavazzana, M., Picard, C., Durandy, A., Fischer, A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75746 · Cited by 288
Self-citationOmori, S. A., Cato, M. H., Anzelon-Mills, A., Puri, K. D., Shapiro-Shelef, M., Calame, K., & Rickert, R. C. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.015 · Cited by 248
Use of Sirolimus in Solid Organ Transplantation
Augustine, J. J., Bodziak, K. A., & Hricik, D. E. (2007) · Drugs · doi:10.2165/00003495-200767030-00004 · Cited by 247
Sander, S., Chu, V. T., Yasuda, T., Franklin, A., Graf, R., Calado, D. P., Li, S., Imami, K., Selbach, M., Di Virgilio, M., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.021 · Cited by 247
PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
Urick, M. E., Rudd, M. L., Godwin, A. K., Sgroi, D., Merino, M., & Bell, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0549 · Cited by 230
Cited by
Coulter, T. I., Chandra, A., Bacon, C. M., Babar, J., Curtis, J., Screaton, N., Goodlad, J. R., Farmer, G., Steele, C. L., Leahy, T. R., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.021 · Cited by 453
Self-citationPI3Kδ and primary immunodeficiencies
Lucas, C. L., Chandra, A., Nejentsev, S., Condliffe, A. M., & Okkenhaug, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.93 · Cited by 342
Self-citationWAVE2 suppresses mTOR activation to maintain T cell homeostasis and prevent autoimmunity
Liu, M., Zhang, J., Pinder, B. D., Liu, Q., Wang, D., Yao, H., Gao, Y., Toker, A., Gao, J., Peterson, A., et al. (2021) · Science · doi:10.1126/science.aaz4544 · Cited by 53
Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant
Tomlinson, P. R., Knox, R. G., Perisic, O., Su, H., Brierley, G. V., Williams, R. L., & Semple, R. K. (2025) · eLife · doi:10.7554/elife.94420.3 · Cited by 2
Metadata
- Authors
- Elkaim, E., Neven, B., Bruneau, J., Mitsui-Sekinaka, K., Stanislas, A., Heurtier, L., Lucas, C. L., Matthews, H., Deau, M.-C., Sharapova, S., Curtis, J., Reichenbach, J., Glastre, C., Parry, D. A., Arumugakani, G., McDermott, E., Kilic, S. S., Yamashita, M., Moshous, D., Lamrini, H., Otremba, B., Gennery, A., Coulter, T., Quinti, I., Stephan, J.-L., Lougaris, V., Brodszki, N., Barlogis, V., Asano, T., Galicier, L., Boutboul, D., Nonoyama, S., Cant, A., Imai, K., Picard, C., Nejentsev, S., Molina, T. J., Lenardo, M., Savic, S., Cavazzana, M., Fischer, A., Durandy, A., & Kracker, S.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 138
- Issue
- 1
- Pages
- 210-218.e9
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2397769881
- Cited by
- 287
- References
- 18
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study. https://app.cochat.ai/papers/10.1016/j.jaci.2016.03.022
- The paper
- Elkaim, E., Neven, B., Bruneau, J., Mitsui-Sekinaka, K., Stanislas, A., Heurtier, L., Lucas, C. L., Matthews, H., Deau, M.-C., Sharapova, S., Curtis, J., Reichenbach, J., Glastre, C., Parry, D. A., Arumugakani, G., McDermott, E., Kilic, S. S., Yamashita, M., Moshous, D., . . . Kracker, S. (2016). Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2016.03.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.